| MetS/total (%) | Model 1 | Model 2 | Model 3 | P for trend* |
---|---|---|---|---|---|
Quartiles of baseline SUA | Â | Â | Â | Â | 0.004 |
Quartile 1 | 84/941 (8.9) | Reference | Reference | Reference | Â |
Quartile 2 | 93/948 (9.8) | 1.11 (0.81–1.51) | 1.10 (0.81–1.50) | 1.08 (0.77–1.50) |  |
Quartile 3 | 117/944 (12.4) | 1.44 (1.07–1.94) | 1.40 (1.04–1.88) | 1.32 (0.95–1.82) |  |
Quartile 4 | 158/946 (16.7) | 2.05 (1.54–2.71) | 1.99 (1.50–2.65) | 1.55 (1.12–2.16) |  |
Per 1 mg/dL increase | – | 1.20 (1.11–1.29) | 1.30 (1.19–1.42) | 1.19 (1.07–1.33) |  |
Baseline hyperuricemia | Â | Â | Â | Â | Â |
No | 423/3,645 (11.6) | Reference | Reference | Reference | Â |
Yes | 29/134 (21.6) | 2.10 (1.38–3.21) | 2.14(1.39–3.29) | 1.47 (0.89–2.38) |  |
Quartiles of absolute changes in SUA during follow–up†|  |  |  |  |  < 0.001 |
Quartile 1 | 93/945 (9.8) | Reference | Reference | Reference | Â |
Quartile 2 | 101/944 (10.7) | 1.10 (0.82–1.48) | 1.05 (0.78–1.42) | 1.23 (0.89–1.71) |  |
Quartile 3 | 107/945 (11.3) | 1.17 (0.87–1.57) | 1.13 (0.84–1.52) | 1.39 (1.00–1.93) |  |
Quartile 4 | 151/945 (16.0) | 1.74 (1.32–2.30) | 1.77 (1.34–2.34) | 1.89 (1.38–2.58) |  |
Quartiles of percent changes in SUA during follow–up‡ |  |  |  |  |  < 0.001 |
Quartile 1 | 88/944 (9.3) | Reference | Reference | Reference | Â |
Quartile 2 | 106/945 (11.2) | 1.23 (0.91–1.66) | 1.19 (0.88–1.61) | 1.32 (0.95–1.82) |  |
Quartile 3 | 113/946 (11.9) | 1.32 (0.98–1.77) | 1.29 (0.96–1.73) | 1.51 (1.09–2.09) |  |
Quartile 4 | 145/944 (15.4) | 1.77 (1.33–2.34) | 1.76 (1.32–2.33) | 2.18 (1.57–3.02) |  |